246 related articles for article (PubMed ID: 34081617)
1. Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study.
Carosi G; Mangone A; Sala E; Del Sindaco G; Mungari R; Cremaschi A; Ferrante E; Arosio M; Mantovani G
Eur J Endocrinol; 2021 Jul; 185(2):289-297. PubMed ID: 34081617
[TBL] [Abstract][Full Text] [Related]
2. DISCORDANCE BETWEEN GH AND IGF-1 LEVELS IN TURKISH ACROMEGALIC PATIENTS.
Cerit ET; Ağbaht K; Demir Ö; Şahin M; Gedik VT; Özcan C; Çorapçıoğlu D
Endocr Pract; 2016 Dec; 22(12):1422-1428. PubMed ID: 27631850
[TBL] [Abstract][Full Text] [Related]
3. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
4. Dynamic tests and basal values for defining active acromegaly.
Tzanela M
Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and treatment responsiveness of patients with acromegaly and a paradoxical GH increase to oral glucose load.
Atquet V; Alexopoulou O; Maiter D
Eur J Endocrinol; 2021 Jul; 185(2):313-321. PubMed ID: 34085950
[TBL] [Abstract][Full Text] [Related]
6. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
Brzana JA; Yedinak CG; Delashaw JB; Gultelkin HS; Cook D; Fleseriu M
Pituitary; 2012 Dec; 15(4):562-70. PubMed ID: 22183781
[TBL] [Abstract][Full Text] [Related]
7. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
[TBL] [Abstract][Full Text] [Related]
8. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
[TBL] [Abstract][Full Text] [Related]
9. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
[TBL] [Abstract][Full Text] [Related]
10. Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I.
Scacchi M; Carzaniga C; Vitale G; Fatti LM; Pecori Giraldi F; Andrioli M; Cattaneo A; Cavagnini F
J Endocrinol Invest; 2011 Oct; 34(9):e291-5. PubMed ID: 21697649
[TBL] [Abstract][Full Text] [Related]
11. Hormonal diagnosis of GH hypersecretory states.
Grottoli S; Gasco V; Ragazzoni F; Ghigo E
J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
[TBL] [Abstract][Full Text] [Related]
12. Limited utility of oral glucose tolerance test in biochemically active acromegaly.
Ribeiro-Oliveira A; Faje AT; Barkan AL
Eur J Endocrinol; 2011 Jan; 164(1):17-22. PubMed ID: 20926592
[TBL] [Abstract][Full Text] [Related]
13. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.
Freda PU; Nuruzzaman AT; Reyes CM; Sundeen RE; Post KD
J Clin Endocrinol Metab; 2004 Feb; 89(2):495-500. PubMed ID: 14764751
[TBL] [Abstract][Full Text] [Related]
14. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
15. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
16. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly.
Freda PU; Reyes CM; Nuruzzaman AT; Sundeen RE; Bruce JN
Pituitary; 2003; 6(4):175-80. PubMed ID: 15237928
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy.
Kinoshita Y; Tominaga A; Usui S; Arita K; Sakoguchi T; Sugiyama K; Kurisu K
Neurosurg Rev; 2016 Apr; 39(2):313-8; discussion 318-9. PubMed ID: 26785642
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly.
Niculescu D; Purice M; Coculescu M
Pituitary; 2013 Jun; 16(2):168-74. PubMed ID: 22562529
[TBL] [Abstract][Full Text] [Related]
19. Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment.
Campana C; Cocchiara F; Corica G; Nista F; Arvigo M; Amarù J; Rossi DC; Zona G; Ferone D; Gatto F
J Clin Endocrinol Metab; 2021 Mar; 106(3):789-801. PubMed ID: 33236108
[TBL] [Abstract][Full Text] [Related]
20. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly.
Dobrashian RD; O'Halloran DJ; Hunt A; Beardwell CG; Shalet SM
Clin Endocrinol (Oxf); 1993 Jun; 38(6):589-93. PubMed ID: 8334745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
